Eli Lilly and Company (NYSE:LLY – Get Rating) announced a quarterly dividend on Monday, May 2nd, RTT News reports. Investors of record on Monday, May 16th will be paid a dividend of 0.98 per share on Friday, June 10th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.35%.
Eli Lilly and has increased its dividend by an average of 14.8% annually over the last three years and has raised its dividend annually for the last 8 consecutive years. Eli Lilly and has a dividend payout ratio of 41.1% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Eli Lilly and to earn $9.69 per share next year, which means the company should continue to be able to cover its $3.92 annual dividend with an expected future payout ratio of 40.5%.
Shares of LLY traded down $7.71 on Monday, reaching $289.56. 113,799 shares of the company’s stock traded hands, compared to its average volume of 2,932,719. The company has a current ratio of 1.23, a quick ratio of 0.97 and a debt-to-equity ratio of 1.68. The stock has a market cap of $275.76 billion, a PE ratio of 42.74, a PEG ratio of 2.31 and a beta of 0.43. The stock’s 50 day simple moving average is $281.25 and its two-hundred day simple moving average is $263.33. Eli Lilly and has a 52-week low of $181.19 and a 52-week high of $314.00.
In other news, SVP Ilya Yuffa sold 1,000 shares of Eli Lilly and stock in a transaction dated Tuesday, February 15th. The stock was sold at an average price of $237.45, for a total value of $237,450.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Marschall S. Runge acquired 202 shares of the firm’s stock in a transaction dated Tuesday, March 1st. The stock was bought at an average price of $246.78 per share, for a total transaction of $49,849.56. The disclosure for this purchase can be found here. Insiders have sold 1,088,551 shares of company stock worth $307,943,730 in the last 90 days. Company insiders own 0.12% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Community Trust NA bought a new stake in shares of Eli Lilly and in the fourth quarter worth about $29,000. Ulland Investment Advisors LLC bought a new stake in shares of Eli Lilly and in the fourth quarter worth about $55,000. SkyView Investment Advisors LLC bought a new stake in shares of Eli Lilly and in the fourth quarter worth about $208,000. Paradigm Financial Partners LLC bought a new stake in shares of Eli Lilly and in the fourth quarter worth about $237,000. Finally, Zullo Investment Group Inc. bought a new stake in shares of Eli Lilly and in the fourth quarter worth about $295,000. 82.75% of the stock is currently owned by institutional investors.
Several brokerages have weighed in on LLY. Sanford C. Bernstein increased their price objective on Eli Lilly and from $250.00 to $300.00 and gave the company a “market perform” rating in a report on Monday, January 3rd. Wells Fargo & Company raised their price target on Eli Lilly and from $280.00 to $305.00 in a report on Friday. Morgan Stanley raised their price target on Eli Lilly and from $364.00 to $369.00 in a report on Friday. Daiwa Capital Markets began coverage on Eli Lilly and in a report on Thursday, March 10th. They issued an “outperform” rating and a $286.00 price target for the company. Finally, DZ Bank raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $291.00 price target for the company in a report on Friday, January 21st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $302.56.
About Eli Lilly and (Get Rating)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- onsemi Is A Deep-Value In The Chip Sector
- Is The FOMC About To Spark A Massive Stock Market Correction?
- Knight-Swift Transportation Stock is a Logistics Winner
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Why is Chevron Stock Falling After Strong Earnings?
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.